• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• News

• News
• Features
• NICE newsletters and alerts
• Events
• Media centre
• NICE annual conference
• Guidance in Focus
• Podcasts
• Videocasts
• Public meetings

2003/047 NICE issues guidance on newer drugs for bipolar disorder

The National Institute for Clinical Excellence has issued guidance on the use of two drugs for treatment of acute mania associated with bipolar I disorder.

In summary, the guidance recommends that olanzapine and valproate semisodium (used as licensed) should be considered as options among the medicines available for the treatment of the acute symptoms of mania associated with bipolar I disorder. The choice of drug should be made jointly by the individual and their doctor after a discussion of the benefits and possible side-effects of each treatment and should take into account the needs of the individual and their particular clinical situation.

2003/047 NICE issues guidance on newer drugs for bipolar disorder 24 September 2003 (92.9Kb 01min 32sec @ 28.8Kbps)

Adobe Acrobat reader required.

This page was last updated: 29 April 2009